Survival rates and HRs for mortality in recipients of less-intensive vs intensive induction therapies within the prospective cohort
| . | 2-y adjusted OS, % . | . | . | |
|---|---|---|---|---|
| Model no.* . | Less intensive . | Intensive . | HR (95% CI) . | P . |
| 1 | ||||
| AML-CM | ||||
| ≤3 | — | 74 | — | — |
| 4-6 | 32 | 52 | 2.44 (1.43-4.17) | .001 |
| 7-9 | 22 | 38 | 1.47 (1.00-2.13) | .05 |
| ≥10 | 12 | 23 | 1.64 (1.11-2.44) | .01 |
| 2 | ||||
| AML-CM | ||||
| 4-6 | 34 | 52 | 1.92 (0.96-3.70) | .06 |
| 7-9 | 41 | 38 | 0.88 (0.56-1.39) | .60 |
| ≥10 | 16 | 22 | 2.47 (0.79-2.13) | .31 |
| 3 | ||||
| AML-CM | ||||
| 4-6 | 48 | 52 | 1.32 (0.58-3.03) | .52 |
| 7-9 | 50 | 38 | 0.67 (0.39-1.14) | .14 |
| ≥10 | 20 | 22 | 1.14 (0.66-1.96) | .64 |
| 4 | ||||
| Age, y | ||||
| 60-69 | 34 | 38 | 1.10 (0.68-1.79) | .70 |
| ≥70 | 21 | 22 | 1.03 (0.68-1.56) | .68 |
| 5 | ||||
| Age, y | ||||
| 60-69 | 40 | 37 | 0.89 (0.53-1.49) | .66 |
| ≥70 | 27 | 22 | 0.82 (0.49-1.35) | .44 |
| . | 2-y adjusted OS, % . | . | . | |
|---|---|---|---|---|
| Model no.* . | Less intensive . | Intensive . | HR (95% CI) . | P . |
| 1 | ||||
| AML-CM | ||||
| ≤3 | — | 74 | — | — |
| 4-6 | 32 | 52 | 2.44 (1.43-4.17) | .001 |
| 7-9 | 22 | 38 | 1.47 (1.00-2.13) | .05 |
| ≥10 | 12 | 23 | 1.64 (1.11-2.44) | .01 |
| 2 | ||||
| AML-CM | ||||
| 4-6 | 34 | 52 | 1.92 (0.96-3.70) | .06 |
| 7-9 | 41 | 38 | 0.88 (0.56-1.39) | .60 |
| ≥10 | 16 | 22 | 2.47 (0.79-2.13) | .31 |
| 3 | ||||
| AML-CM | ||||
| 4-6 | 48 | 52 | 1.32 (0.58-3.03) | .52 |
| 7-9 | 50 | 38 | 0.67 (0.39-1.14) | .14 |
| ≥10 | 20 | 22 | 1.14 (0.66-1.96) | .64 |
| 4 | ||||
| Age, y | ||||
| 60-69 | 34 | 38 | 1.10 (0.68-1.79) | .70 |
| ≥70 | 21 | 22 | 1.03 (0.68-1.56) | .68 |
| 5 | ||||
| Age, y | ||||
| 60-69 | 40 | 37 | 0.89 (0.53-1.49) | .66 |
| ≥70 | 27 | 22 | 0.82 (0.49-1.35) | .44 |
Comparisons stratified according to AML-CM score 4-6, 7-9, and ≥10. No comparisons were performed for patients with AML-CM score ≤3 because all received intensive therapies. Higher HR indicates increased mortality with less-intensive therapies. Overall survival (OS) rates compare adjusted rates, so survival rates of less-intensive recipients were adjusted for characteristics of recipients of intensive therapies per previously published methods.17
Models adjusted as follows: model 1, adjusted for diagnosis (newly diagnosed AML, relapsed/refractory AML, high-risk myelodysplastic syndrome [MDS]), closely resembling comparison in retrospective cohort; model 2, adjusted for diagnosis (newly diagnosed AML, relapsed/refractory AML, high-risk MDS), age (65-69, 70-74, ≥75 y), and KPS (≤70%, 75% to 100%); model 3, adjusted for diagnosis (newly diagnosed AML, relapsed/refractory AML, high-risk MDS), age (65-69, 70-74, ≥75 y), KPS (≤70%, 75% to 100%), and physician perception of cure chance (≥50%, 25% to 49%, 10% to 24%, <10%, missing); model 4, adjusted for diagnosis (newly diagnosed AML, relapsed/refractory AML, high-risk MDS), KPS (≤70%, 75% to 100%), and AML-CM (4-6, 7-9, ≥10); and model 5, adjusted for diagnosis (newly diagnosed AML, relapsed/refractory AML, high-risk MDS), KPS (≤70%, 75% to 100%), physician perception of cure chance (≥50%, 25% to 49%, 10% to 24%, <10%, missing), and AML-CM (4-6, 7-9, ≥10).